← Browse by Condition
Medical Condition

duchenne muscular dystrophy

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 2, Phase 1, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for duchenne muscular dystrophy sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.

  • Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
  • Phase 1–4 studies from early safety trials to post-marketing surveillance
  • NIH, pharmaceutical sponsor, and academic medical center studies worldwide
  • AI-powered plain-language summary available for every trial listing

Frequently Asked Questions — duchenne muscular dystrophy Clinical Trials

How many clinical trials are currently recruiting for duchenne muscular dystrophy?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for duchenne muscular dystrophy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for duchenne muscular dystrophy?
duchenne muscular dystrophy research spans Phase 1 (2 trials), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a duchenne muscular dystrophy clinical trial?
Eligibility criteria for duchenne muscular dystrophy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
2
Phase 2
2
Top Sponsors
Massachusetts General Hospital 1 trial
Italfarmaco 1 trial
Insmed Gene Therapy LLC 1 trial
Wave Life Sciences Ltd. 1 trial
CureDuchenne 1 trial

Recruiting Clinical Trials

NCT05019625
Recruiting

Biomarker Development for Muscular Dystrophies

Enrollment
465 pts
Location
United States
Sponsor
Massachusetts General Hospital
View Trial →
NCT06769633 Phase 2
Recruiting

Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old

Enrollment
18 pts
Location
Belgium, Italy, Neth...
Sponsor
Italfarmaco
View Trial →
NCT06817382 Phase 1
Recruiting

A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)

Enrollment
12 pts
Location
United States
Sponsor
Insmed Gene Therapy LLC
View Trial →
NCT04906460 Phase 1, Phase 2
Recruiting

Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Enrollment
26 pts
Location
United States, Jorda...
Sponsor
Wave Life Sciences Ltd.
View Trial →
NCT04972604
Recruiting

CureDuchenne Link®: A Resource for Research

Enrollment
5,000 pts
Location
United States
Sponsor
CureDuchenne
View Trial →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology